Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URLC10, VEGFR1, and VEGFR2 Peptide Vaccine in Refractory NSCLC
NCT00673777Phase 2Unknown
- Sponsor
- The University of Tokyo
- Start
- May 2008
- Primary completion
- Apr 2009
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of URLC10, LY6K + VEGFR1 + VEGFR2, elpamitide in non-small cell lung cancer (NSCLC), sponsored by The University of Tokyo. Status: unknown.
02
Drugs
URLC10LY6K + VEGFR1 + VEGFR2elpamitide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00673777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00673777.